pág. 8338
ello, hoy por hoy debemos contar con la mayor información que nos permita ejercer acorde a los
requerimientos de los pacientes.
REFERENCIAS BIBLIOGRAFICAS
1. Fuster, V, Gersh B, Giuliani E Tajik A, Brandenburg R, Frye R. The natural history of idiopathic
dilated cardiomyopathy Am J Cardiol 1981;47:525-530.
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management
of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic
Therapy. Chest. 2004;126(3 Suppl):204S-33. http://doi.org/bpbzd5.
3. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin
control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 2009;15(3):244-
52. http://doi.org/bc7z.
4. Eikelboom JW, Weitz JI. New Anticoagulants. Circulation. 2010;121(13):1523-32.
http://doi.org/dzfbf2.
5. Azoulay L et al. Eur Heart J, Jul 21;35(28):1881-7. doi: 10.1093/eurheartj/eht499. Epub 2013 Dec
18.
6. Jensen AS, Idorn L, Nørager B, Vejlstrup N; Sondergaardet L. Anticoagulation in adults with
congenital heart disease. The Who, the When and the How. Heart, 2015;101(6):424-429.
7. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of
rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug. Discov. 2011;10(1):61-75.
http://doi.org/d74nsh.
8. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinri¬chsen H, et al. Effect of hepatic
impairment on the pharmaco¬kinetics and pharmacodynamics of a single dose of rivaroxaban, an
oral, direct Factor Xa inhibitor. Br. J. Clin. Pharmacol. 2013;76(1):89-98. http://doi.org/bc8n.
9. Kakkar AK, Brenner B, Dahl OE, Eriksson B, Mouret P, Muntz J, et al. Extended duration
rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total
hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-9.
http://doi.org/dg52wj.